Private Placement

Ditching high upfront costs, OutBack Power's new Advantage Program offers home battery backup as a managed service, aiming to democratize energy resilience.

Two-time Grammy winner Laufey receives ASCAP's Creative Voice Award, celebrating her genre-fusing sound and her mission to empower young musicians.

A new VC-backed program is giving elite female athletes the tailored health tools sports science has long ignored, aiming to optimize performance and longevity.

Cookeville wealth firm Cravens & Company Advisors hires a CFA charterholder as Director of Investments and promotes an analyst in a strategic expansion.

With a $137M war chest, Sidewinder Therapeutics is advancing a new class of ultra-precise cancer drugs aimed at tumors that have long evaded treatment.

As AI drives DRAM costs to a breaking point, one startup's software uses AI to fight back, promising to slash server costs and expand memory capacity.

As AI chatbots transform how renters find apartments, one VC firm is betting on the startups that will help properties stay visible in a post-search world.

With its lead cancer drug advancing and a strong balance sheet, Nurix will detail its vision for protein degradation at a key investor conference.

As U.S.-Mexico trade booms, a new AI platform aims to automate complex customs rules ahead of Mexico's strict 2026 legal reforms, a critical test for shippers.

The iconic wagon maker launches a powerful, compact eBike to make family transportation easier, safer, and more joyful. Is this the car-killer for cities?

A new partnership brings a groundbreaking protocol for corneal blindness to Chicago, expanding a national network dedicated to restoring vision for thousands.

A new Bezos Academy on a senior living campus offers free early education, tackling childcare costs and forging powerful bonds between young and old.

Backed by a $41.3M ARPA-H award, SonoNeu is pioneering sonogenetics, a non-invasive therapy using ultrasound to control cells and treat nerve pain.

A new trial for advanced liver cancer tests visugromab, a drug aiming to overcome immunotherapy resistance and reverse debilitating cancer-related wasting.

With zero debt and millions in cash, Atlas Energy is hunting for global oil and gas deals. But can it escape its unique regulatory 'Sandbox' status?

A new botanical drug candidate, NFL-102, targets the deep neural roots of addiction, moving beyond symptom management to offer a lasting cure for smokers.

With millions of illegal school bus passings a year, new tech like extended stop arms offers a proactive solution. But can it overcome cost and driver apathy?

Vyome is set to present promising Phase 2 data for VT-1953, a first-in-class treatment for a debilitating cancer complication with no approved drugs.

This April, families nationwide are walking to fund a new strategy for Lennox-Gastaut Syndrome, aiming to slash diagnosis times and find real cures.

Apnimed has secured up to $150M to launch AD109, a potential first-ever pill for sleep apnea, promising relief for millions tired of CPAP machines.